The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

The American College of Cardiology (ACC) develops a number of policy documents to
provide members with guidance on clinical topics. Although clinical practice guidelines …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with
significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are …

Background: Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the …

Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Background An integrated care approach might be of benefit for clinical outcomes of patients
with atrial fibrillation (AF). This study evaluated whether compliance with the Atrial fibrillation …

Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …